Skip to main content

Table 3 Cost-utility analysis for the different vaccination policies, by model and by time horizon

From: The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study

Model TI

Model PI

Policy

Total costa

QALY lossb

ICERc

NMBkd

NMBve

Policy

Total costa

QALY lossb

ICERc

NMBkd

NMBve

Time horizon = 25 years

 No vacc.

1812

455

–

–

–

No vacc.

2023

538

–

–

–

 VR

1831

446

2219

110

324

VR

2066

537

WD

−37

−28

 HZR

2540

413

WD

−94

963

HZR

2722

481

WD

143

1548

 VRHZR

2555

402

WD

50

1371

VRHZR

2757

477

WD

166

1667

 HZR + CU

2823

380

WD

109

1975

HZR + CU

2995

444

WD

436

2782

 VRHZR + CU

2836

369

12,989

265

2414

VRHZR + CU

3028

439

10,175

476

2944

Time horizon = 50 years

 No vacc.

2668

691

–

–

–

No vacc.

3145

885

–

–

–

 VR

2643

680

Cost-saving

190

466

VR

3240

924

SD

−679

−1654

 VRHZR

3563

576

WD

820

3679

HZR

3989

745

6031

1255

4754

 HZR

3601

593

SD

531

2970

VRHZR

4047

767

SD

878

3844

 VRHZR + CU

3841

543

8722

1052

4760

HZR + CU

4258

707

6984

1563

6022

 HZR + CU

3880

560

SD

749

4017

VRHZR + CU

4313

727

SD

1204

5156

Time horizon = 85 years

 No vacc.

3092

798

–

–

–

No vacc.

3724

1059

–

–

–

 VR

2962

759

Cost-saving

717

1695

VR

3704

1072

1517

−174

−497

 VRHZR

3984

634

8170

1570

5674

VRHZR

4572

874

4375

1934

6571

 HZR

4119

676

SD

805

3859

HZR

4627

878

SD

1824

6367

 VRHZR + CU

4264

600

8266

1799

6752

VRHZR + CU

4842

834

6829

2257

7881

 HZR + CU

4402

643

SD

1020

4904

HZR + CU

4898

839

SD

2128

7632

  1. All outcomes are reported with a 3% discount rate for both benefits and costs
  2. aAccounting for cost of disease and cost of policy, in million EUR
  3. bIn thousands
  4. cSD strong dominance (a policy is dominated when the alternative is less costly and more effective), WD weak dominance (a policy is dominated when its ICER is larger than that of a policy with higher effectiveness). The ICER is measured in EUR/QALY gained
  5. dBased on the marginal productivity of the national health system (t = 15,000 EUR) and calculated with respect to no vaccination, in million EUR
  6. eBased on the consumers’ willingness to pay (t = 40,000 EUR) and calculated with respect to no vaccination, in million EUR
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us